Related references
Note: Only part of the references are listed.Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
A. F. C. Okines et al.
ANNALS OF ONCOLOGY (2013)
D2 Lymphadenectomy with Surgical Ex Vivo Dissection into Node Stations for Gastric Adenocarcinoma Can Be Performed Safely in Western Patients and Ensures Optimal Staging
Benjamin Schmidt et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
Y-K Kang et al.
BRITISH JOURNAL OF CANCER (2013)
Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
Terence C. Chua et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
Jeeyun Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
Stephen R. Smalley et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2012)
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
Jan Trost Jorgensen et al.
JOURNAL OF CANCER (2012)
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
Johan L. Dikken et al.
BMC CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Curative treatment of oesophageal carcinoma: current options and future developments
Maria C. Wolf et al.
RADIATION ONCOLOGY (2011)
Chemotherapy for Operable Gastric Cancer: Current Perspectives
Vikram K. Jain et al.
INDIAN JOURNAL OF SURGICAL ONCOLOGY (2011)
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis
Xavier Paoletti et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Impact of the Extent of Surgery and Postoperative Chemoradiotherapy on Recurrence Patterns in Gastric Cancer
Johan L. Dikken et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Ilfet Songun et al.
LANCET ONCOLOGY (2010)
Chemotherapy for advanced gastric cancer
Anna Dorothea Wagner et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer
Jae-Lyun Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Re: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence - Reply
H Pohl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial
M Degiuli et al.
EJSO (2004)
Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial
HH Hartgrink et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan Clinical Oncology Group study JCOG 0110-MF
T Sano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2002)
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
JS Macdonald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of adjuvant chemotherapy versus central after curative resection for gastric cancer: 5-year follow-up
B Neri et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
